Suboxone $30 Million Price-Fixing Settlement

Indivior, a well-known pharmaceutical company, has agreed to a $30 million settlement in a class-action lawsuit. The lawsuit alleged that Indivior violated state antitrust, consumer protection, and unjust enrichment laws in the United States. This alleged violation reportedly led to a competitive disadvantage and caused class members to overpay for Co-Formulated Buprenorphine/Nalaxone (Suboxone and/or its AB-rated generic equivalent).

Unraveling the $30 Million Settlement

The settlement amount agreed upon by Indivior is a substantial $30 million. This amount will be used to create a Settlement Fund, which will be distributed amongst the eligible End Payor Class members who submit valid claim forms. The Settlement Fund will also be utilized to cover attorneys' fees, litigation expenses, and service awards to the named plaintiffs.

Key Dates to Remember

There are several important dates associated with this settlement:

• Fairness Hearing: A Fairness Hearing was held on October 19, 2023.
• Deadline to File a Claim: February 17, 2024.

Who are the Class Members?

Class Members are defined as all persons or entities who purchased and/or paid for some or all of the purchase price for Co-Formulated Buprenorphine/Nalaxone (Suboxone and/or its AB-rated generic equivalent) in any form, for consumption by themselves, their families, or their members, employees, plan participants, beneficiaries, or insureds in several states and the District of Columbia between December 22, 2011, and August 21, 2023. However, claimants who exclude themselves from the End Payor Class will not be eligible for any settlement benefits.

What Can Class Members Claim?

The amount of the award depends on the number of valid claims submitted and approved. There is no specific tier system or award schedule mentioned on the settlement website at this time.

Is Proof Required to Claim the Reward?

Yes, proof is required to claim the reward. Claimants will need to submit a valid Claim Form with:

1. Records from your pharmacy showing that you purchased Suboxone and its AB-rated generic equivalents at least once; or
2. A note from your doctor (or records) describing the amount of Suboxone and its AB-rated generic equivalents you were prescribed.

Why is There a Class Action Settlement?

The class-action lawsuit alleges that Indivior violated state antitrust, consumer protection, and unjust enrichment laws in the United States, resulting in harm to competition and causing class members to overpay for Co-Formulated Buprenorphine/Nalaxone (Suboxone and/or its AB-rated generic equivalent). The defendants deny any wrongdoing. The Court has scheduled a Fairness Hearing on October 19, 2023, to consider final approval of the settlement. Class members have the option to do nothing and remain a member of the End Payor Class, but they must submit a Claim Form to recover any settlement benefits. The deadline for submitting the Claim Form is February 17, 2024.